IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Inclusion Criteria: * Patients older than 18 years of age. * Histological confirmed diagnosis of a prostate adenocarcinoma, melanoma or colon cancer * At least one measurable site of disease as evidenced by CT or MRI, RECIST criteria in soft tissue OR lymph nodes and OR tumor markers as appropriate * Rising PSA in 3 consecutive weeks taken at least one week apart with a value of at least 5 ng/mL * Testosterone that is less than 50 ng/dL in prostate patients * Prostate cancer patients receiving radiation therapy that is less than 30% of pelvic/total bone mass and where acute radiation toxicity is resolved * ECOG Performance status 0- 2 * WBC \> 1,500 cells/mm3, hemoglobin \> 9 g/dL, and platelets \> 100,000 cells/mm3 and \< 500,000 cells/mm3 * Adequate renal function: serum creatinine \< 2.0 mg/dL, or CCT\>= 50 ml/min * Life expectancy of at least 3 months * Willing to participate in a 6 month follow-up * Female patients of child-bearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Post menopausal women must be amenorrheic for at least 12 months to be considered of non- childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug. * Patients who have given written informed consent Exclusion Criteria: * Patients suffering from primary or metastatic brain or spinal tumor. * Patients with known sensitivity to any of the components of the IVIG formulation excipients. * IgA levels \<=60mg/dl . * Treatment with IVIG 6 months prior to study start * Patients that are with known seropositivity for HIV or with a known diagnosis of human immunodeficiency virus (HIV) infection. (AIDS) * Patients with significant diseases, active infection or uncontrolled medical condition (e.g., pulmonary, neurological, cardiovascular, gastrointestinal, genitourinary) considered high risk for investigational new drug treatment/ who in the opinion of the investigator would be excluded from the study * Female patients who are pregnant or breast-feeding. * Patient has a severe and/or uncontrolled renal failure. * Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis). * Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent and who in the opinion of investigator, are unlikely to comply with the study protocol * Patients who are currently participating or have participated in another clinical trial in the last 30 days. * Patients who have undergone chemotherapy in the last 4 weeks * Patients who are being treated with antibiotic treatment for an active infection